Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Saved in:
| Title: | Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. |
|---|---|
| Authors: | Petersenn S; ENDOC Center for Endocrine Tumors, Hamburg, Germany. stephan.petersenn@endoc-med.de., Salgado LR; Division of General Internal Medicine, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil., Schopohl J; Medizinische Klinik IV, University of Munich, Munich, Germany., Portocarrero-Ortiz L; Department of Neuroendocrinology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico., Arnaldi G; Division of Endocrinology, Polytechnic University of Marche Region, Ancona, Italy., Lacroix A; Division of Endocrinology, Centre hospitalier de l'Université de Montréal, Montreal, Canada., Scaroni C; Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy., Ravichandran S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kandra A; Novartis Pharma AG, Basel, Switzerland., Biller BMK; Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, MA, USA. |
| Source: | Endocrine [Endocrine] 2017 Jul; Vol. 57 (1), pp. 156-165. Date of Electronic Publication: 2017 Jun 09. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 9434444 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-0100 (Electronic) Linking ISSN: 1355008X NLM ISO Abbreviation: Endocrine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 28597198 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Petersenn+S%22">Petersenn S</searchLink>; ENDOC Center for Endocrine Tumors, Hamburg, Germany. stephan.petersenn@endoc-med.de.<br /><searchLink fieldCode="AU" term="%22Salgado+LR%22">Salgado LR</searchLink>; Division of General Internal Medicine, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Schopohl+J%22">Schopohl J</searchLink>; Medizinische Klinik IV, University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Portocarrero-Ortiz+L%22">Portocarrero-Ortiz L</searchLink>; Department of Neuroendocrinology, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Arnaldi+G%22">Arnaldi G</searchLink>; Division of Endocrinology, Polytechnic University of Marche Region, Ancona, Italy.<br /><searchLink fieldCode="AU" term="%22Lacroix+A%22">Lacroix A</searchLink>; Division of Endocrinology, Centre hospitalier de l'Université de Montréal, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Scaroni+C%22">Scaroni C</searchLink>; Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy.<br /><searchLink fieldCode="AU" term="%22Ravichandran+S%22">Ravichandran S</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kandra+A%22">Kandra A</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Biller+BMK%22">Biller BMK</searchLink>; Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229434444%22">Endocrine</searchLink> [Endocrine] 2017 Jul; Vol. 57 (1), pp. 156-165. <i>Date of Electronic Publication: </i>2017 Jun 09. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9434444 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1559-0100 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221355008X%22">1355008X </searchLink><i>NLM ISO Abbreviation: </i>Endocrine <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28597198 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s12020-017-1316-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 156 Titles: – TitleFull: Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Petersenn S – PersonEntity: Name: NameFull: Salgado LR – PersonEntity: Name: NameFull: Schopohl J – PersonEntity: Name: NameFull: Portocarrero-Ortiz L – PersonEntity: Name: NameFull: Arnaldi G – PersonEntity: Name: NameFull: Lacroix A – PersonEntity: Name: NameFull: Scaroni C – PersonEntity: Name: NameFull: Ravichandran S – PersonEntity: Name: NameFull: Kandra A – PersonEntity: Name: NameFull: Biller BMK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2017 Jul Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1559-0100 Numbering: – Type: volume Value: 57 – Type: issue Value: 1 Titles: – TitleFull: Endocrine Type: main |
| ResultId | 1 |
